������̳

In order to support tech start-ups in their post-maturity or pre-seed stage, the French government’s “Investments for the Future” program endowed the French Tech Seed investment fund with €400 million. To be eligible, start-ups must first have been certified by referrers approved by BPIFrance.

“This initiative is an excellent opportunity for start-ups to accelerate their early stages of development and thus their access to greater funding or to bringing a product to market.” Jérémie Weber, Head of Start-ups Division at Institut Curie

The PSL Tech Seed consortium, which is sponsored by PSL and includes Institut Pasteur, was one of the first grantees and became a certified referrer in January 2019. This status was renewed in early 2021 for a period of 2 years.

PSL Tech Seed is open to all PSL and Institut Pasteur start-ups, across all disciplines and fields of application. It will serve as a force multiplier for the private funding obtained by these start-ups, with a major impact on their development.

The startups created

Thirteen projects from within the PSL – Pasteur ecosystem have been certified by PSL Tech Seed since the mechanism was created in January 2019.

• (ENS - PSL): Develops innovative therapeutic solutions that can be bioproduced from the extracellular vesicles of microalgae.
• (ENS-PSL): Calculates affinities between molecules and therapeutic targets for drug design and drug discovery.
• (ENS-PSL): Develops quantum processors using carbon nanotubes to accelerate complex computations and develop the computer of the future.
•  (Chimie Paris-PSL): Develops a revolutionary technology for chemical synthesis via a combination of heterogeneous catalysis and cold plasma, at ambient temperature and pressure, with no pretreatment required.
• (Institut Curie): Creates a technology platform to optimize the efficacy and safety of cell therapies for cancer and chronic illness.
• (Institut Curie): Develops a new nanoscale additive manufacturing technology that can apply any material to any surface, with unprecedented design freedom.
• (ESPCI Paris -PSL, ENS-PSL): Develops neurofunctional acoustic imaging solutions for research and clinical applications.
• (ESPCI Paris – PSL): Offers a multimodal, 2D single-cell analysis system for fundamental, applied, and clinical research as well as diagnostics.
•  (ENS – PSL): Offers innovative solutions based on the latest advances in cryptography for secure end-to-end data storage and synchronization.
•  (Mines Paris – PSL): offers a biogas collection, purification and liquefaction solution that significantly lowers the profitability thresholds and makes it possible to develop methanation near sources of production.
• (Institut Curie): Develops molecular diagnostics and precision medicine solutions based on genomic analysis and biomarker identification.
• (Mines Paris – PSL): Offers all the tools needed to generate true-to-life synthesized images that are indistinguishable from real photographs of an object.